259 related articles for article (PubMed ID: 12218235)
21. Skin and oral lesions associated to imatinib mesylate therapy.
Basso FG; Boer CC; Corrêa ME; Torrezan M; Cintra ML; de Magalhães MH; da Silva Santos P; de Souza CA
Support Care Cancer; 2009 Apr; 17(4):465-8. PubMed ID: 19037666
[TBL] [Abstract][Full Text] [Related]
22. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Kuwano Y; Asahina A; Watanabe R; Fujimoto M; Ihn H; Tamaki K
Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457
[No Abstract] [Full Text] [Related]
23. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
Brouard MC; Prins C; Mach-Pascual S; Saurat JH
Dermatology; 2001; 203(1):57-9. PubMed ID: 11549802
[TBL] [Abstract][Full Text] [Related]
24. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect.
Dalmau J; Peramiquel L; Puig L; Fernández-Figueras MT; Roé E; Alomar A
Br J Dermatol; 2006 Jun; 154(6):1213-6. PubMed ID: 16704665
[No Abstract] [Full Text] [Related]
25. [Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy].
Le Nouail P; Viseux V; Chaby G; Billet A; Denoeux JP; Lok C
Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):686-8. PubMed ID: 17053739
[TBL] [Abstract][Full Text] [Related]
26. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
Vinay K; Yanamandra U; Dogra S; Handa S; Suri V; Kumari S; Khadwal A; Prakash G; Lad D; Varma S; Malhotra P
Int J Dermatol; 2018 Mar; 57(3):332-338. PubMed ID: 29266186
[TBL] [Abstract][Full Text] [Related]
27. Lichenoid eruption due to imatinib.
Prabhash K; Doval DC
Indian J Dermatol Venereol Leprol; 2005; 71(4):287-8. PubMed ID: 16394444
[No Abstract] [Full Text] [Related]
28. Imatinib mesylate induced erythroderma.
Sanghavi SA; Dongre AM; Khopkar US
Indian J Dermatol Venereol Leprol; 2012; 78(3):408. PubMed ID: 22565463
[No Abstract] [Full Text] [Related]
29. Pseudoporphyria induced by imatinib mesylate.
Pérez NO; Esturo SV; Viladomiu Edel A; Moreno AJ; Valls AT
Int J Dermatol; 2014 Feb; 53(2):e143-4. PubMed ID: 23451912
[No Abstract] [Full Text] [Related]
30. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia.
Deguchi N; Kawamura T; Shimizu A; Kitamura R; Yanagi M; Shibagaki N; Matsue H; Shimada S
Br J Dermatol; 2006 Jun; 154(6):1216-8. PubMed ID: 16704666
[No Abstract] [Full Text] [Related]
31. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
[TBL] [Abstract][Full Text] [Related]
32. Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate.
Kagimoto Y; Mizuashi M; Kikuchi K; Aiba S
Int J Dermatol; 2014 Mar; 53(3):e161-2. PubMed ID: 23786260
[No Abstract] [Full Text] [Related]
33. Imatinib mesylate-induced lichenoid drug eruption.
Penn EH; Chung HJ; Keller M
Cutis; 2017 Mar; 99(3):189-192. PubMed ID: 28398413
[TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate-induced severe lichenoid rash.
; De D; Malhotra P; Saikia UN
Indian J Dermatol Venereol Leprol; 2014; 80(1):93-5. PubMed ID: 24448145
[No Abstract] [Full Text] [Related]
35. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
Gambillara E; Laffitte E; Widmer N; Decosterd LA; Duchosal MA; Kovacsovics T; Panizzon RG
Dermatology; 2005; 211(4):363-5. PubMed ID: 16286749
[TBL] [Abstract][Full Text] [Related]
36. Imatinib: a designer drug, another cutaneous complication.
Dickens E; Lewis F; Bienz N
Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
[TBL] [Abstract][Full Text] [Related]
37. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
[TBL] [Abstract][Full Text] [Related]
38. Skin fragility and blistering with imatinib mesylate.
Verma SM; Murphy G
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):496-8. PubMed ID: 19925597
[No Abstract] [Full Text] [Related]
39. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
Raanani P; Goldman JM; Ben-Bassat I
J Clin Oncol; 2002 Feb; 20(3):869-70. PubMed ID: 11821474
[No Abstract] [Full Text] [Related]
40. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
Ikeda K; Shiga Y; Takahashi A; Kai T; Kimura H; Takeyama K; Noji H; Ogawa K; Nakamura A; Ohira H; Sato Y; Maruyama Y
Leuk Lymphoma; 2006 Jan; 47(1):155-7. PubMed ID: 16321842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
